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Background: Metastasis in the axillary lymph nodes is the most important known prognostic factor for breast
cancer. We aimed to investigate the contribution of the radioisotope tracer method to the dye-only method by
performing sentinel lymph node biopsy on the same patient group during a single surgical session.
Methods: Forty-two patients who underwent operations in our clinic from February 2010 to October 2011 and with
masses of <5 cm and clinically and radiologicallly negative axilla (T1-2 N0) were prospectively included in this study.
After paraffin examination results were obtained, the numbers and metastatic states of the lymph nodes that were
unidentifiable during surgery (although they were stained) but were detected by a gamma probe, lymph nodes that
were only stained, lymph nodes that were only radioactive (hot), and lymph nodes that were both stained and
radioactive (stained-hot) were determined in all patients. In patients who underwent axillary lymph node dissection,
the total numbers of lymph nodes removed and their metastatic states were determined separately.
Results: At least one blue-stained sentinel lymph node was identified in all patients during the blue-stained lymph node
detection stage. The average number of sentinel nodes removed at this stage was 2.1 ± 1.1. In the second surgical stage
(the stage in which nodes with axillary counts were investigated with the gamma probe) in these 41 patients, at least
one additional hot node was removed, or at least one of the nodes that was removed because it was blue was also hot.
In addition to the lymph nodes removed in the dye stage, 34 hot lymph nodes were excised from 21 patients. Overall,
the average number of hot lymph nodes removed was 2.9 ± 1.5. In all patients, subsequent frozen sections and
histopathological examinations were 100% concordant with the sentinel lymph nodes that were removed; the stained
sentinel lymph nodes that were removed first did not affect the decision to perform axillary dissection.
Conclusion: The results of our study indicate that performing sentinel lymph node biopsy with dye only is sufficient and
as effective as the combined method.
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In breast cancer, the most important known prognostic
factor is the presence of metastasis in the axillary lymph
nodes [1]. In early-stage breast cancer, knowledge of the
presence or absence of axillary involvement can be
obtained by axillary lymph node dissection (ALND).
However, it can also be obtained with high sensitivity
and accuracy by sentinel lymph node biopsy (SLNB),
which is a much less invasive method [2-4]. SLNB can
be performed using a dye-only method, a radioisotope-
only method, or a combination of the two methods.
With all three methods, the status of the axilla can re-
portedly be presented with high sensitivity and accuracy
and acceptable false-negative rates [5-7].
Compared with the combination method, performance
of SLNB with the dye-only method is an inexpensive
and practical technique that does not require involve-
ment of the nuclear medicine department. Randomised
studies that compared the combination method with the
dye-only method could not adequately demonstrate that
the combination method was superior to the dye-only
method; this topic is still under debate [5,7-14]. Import-
ant studies on this topic have been conducted by apply-
ing and comparing the different techniques using
different randomised patients. However, comparison of
the two techniques on the same patients during the
same surgical session will completely equalise patient-
derived factors and facilitate the acquisition of more ac-
curate results.
In this study, we aimed to investigate the contribution
of the radioisotope tracer method to the dye-only
method by performing SLNB on the same patient group
during a single surgical session.
Methods
Forty-two patients who underwent operations in our
surgical department (a level three referral hospital) be-
tween February 2010 and October 2011 with masses of
<5 cm and clinically and radiologically negative axillae
(T1-2 N0) were prospectively included in this study. A
total of 123 patients underwent operations within this
time frame in our institution (56 SLNB and 67 ALND).
Fourteen of 56 patients (SLNB) were excluded from our
study because they underwent operations by different
surgeons. The exclusion criteria were pregnancy, having
a history of axillary surgery, having received radiotherapy
in the axillary region, having received neoadjuvant
chemotherapy, and having allergies to the dye and/or al-
bumin. The age of the patients, their age at menarche,
whether or not they were in menopause, the localisation
of the tumour, the radiologic Breast Imaging Reporting
and Data System (BI-RADS) score, the type of biopsy
performed for diagnosis, the type of surgery that took
place, the knowledge of the tumour T stage, and thehistological results were recorded on a form that was
prepared prospectively. The study was approved by
Dr. Lutfi Kirdar of the Kartal Training and Research
Hospital Ethics Committee. Informed consent forms
were obtained from all patients.
In the nuclear medicine clinic of our hospital on the
morning of the surgery, 0.2 ml and 20 Mbq (99 m) of
Tc-nanocolloid (CIS Bio International, France) was
injected around the tumour in all patients. In excisional
biopsy patients, it was also subcutaneously injected
around the excision region (pouch). Immediately follow-
ing the injection, the SLN was imaged by performing
both a dynamic and static lymphoscintigraphy series.
The marking of the skin projection of the SLN with a
pen, as is performed in routine applications, was not
performed in these patients. Patients underwent opera-
tions within 2 hours.
An experienced surgical resident performed a scintilla-
tion count with a gamma probe. He compared the re-
sults with the lymphoscintigraphy report and recorded
the data. He did not share this information with the pri-
mary surgeon until the end of the first stage (dye guid-
ance stage) of the surgical procedure. The primary
surgeon was informed after the use of patent blue violet
dye and performed all surgeries with this knowledge. For
all patients, SLNBs were performed by the same surgeon
under general anaesthesia. During the surgery, 1% patent
blue violet, which was prepared in 5-ml sterile ampoules
(Sigma-Aldrich, Germany) in the Istanbul University
Faculty of Pharmacy, was used as the dye. The SLNB
was performed by injecting one entire ampoule subcuta-
neously lateral to the incision in patients with a biopsy
scar in the upper outer quadrant of the breast and sub-
cutaneously in the subareolar region in the other pa-
tients. Following the injection, the dye was gently
massaged toward the axilla for 7 minutes in all patients.
One centimetre below the axillary line, a small trans-
verse incision was applied and the stained lymph chan-
nel, which led to the SLN, was detected. By searching
the SLNB, no additional effort was applied to extract the
blue channels, but these channels were also removed
with the SLN. After the axillary dye guidance procedure
was completed and all stained nodes were believed to
have been excised, the primary surgeon was informed
about the location and number of the foci found by
lymphoscintigraphy, the foci detected, and their count
values as detected by the hand-held gamma probe in the
axilla before the incision. Counts from the excised
stained lymph nodes were taken and recorded. The
remaining axillary lymph nodes were then scanned with
an intra-operative hand-held gamma probe; if there were
additional lymph nodes that emitted counts, they were
also excised. The lymph nodes were specially examined
to determine whether they retained the dye and thus
Table 1 Patient clinical and demographic information





Upper outer quadrant 19 (45%)
Lower outer quadrant 3 (7%)
Upper inner quadrant 6 (14%)
Lower inner quadrant 5 (12%)
Mammographic BI-RADS
BI-RADS 0 7 (17%)
BI-RADS 3 2 (5%)
BI-RADS 4a 2 (5%)
BI-RADS 4b 2 (5%)
BI-RADS 4c 7 (17%)
BI-RADS 5 21 (50%)
Ultrasonography BI-RADS
BI-RADS 0 1 (2%)
BI-RADS 3 1 (2%)
BI-RADS 4a 3 (7%)
BI-RADS 4b 3 (7%)
BI-RADS 4c 13 (31%)
BI-RADS 5 21 (50%)
Lumpectomy + SLN 19 (45%)
Lumpectomy + AD 12 (29%)
Mastectomy + SLN 3 (7%)







Invasive Ductal 38 (90%)
Invasive Lobular 1 (2%)
Mucinous carcinoma 2 (5%)
Squamous cell carcinoma 1 (2%)
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properties and count values were recorded, and the
nodes were numbered and sent for peri-operative patho-
logical examination. In the pathological examination,
SLNs were sectioned into two parts along their long axes
by a pathologist experienced in this field. Imprint prepa-
rations were prepared from the cross-sections. Prepara-
tions were stained with haematoxylin-eosin (H-E). One
half of each SLN was reserved for paraffin examination.
The other half was examined macroscopically by prepar-
ing 2-mm sections, and appropriate sections were flash-
frozen. Samples were taken from frozen preparations,
stained with H-E, and examined by light microscopy.
Two-millimetre sections were prepared from the other
half of the lymph node, and paraffin blocks were
obtained from each segment after they were fixed in
Hollande solution. Serial sections 3 to 4 μm in thickness
were prepared from these blocks. Samples were taken
and stained with H-E; a standard examination was then
performed. Based on the results of the frozen sections
(FSs), axillary dissection was performed for the patient if
required. Axillary lymph node dissection was not
performed on patients whose FS results were negative.
After the results of the paraffin examinations for all
patients were obtained, the numbers and metastatic
states of the lymph nodes were determined separately
for those lymph nodes that were not noted during the
dye surgery (although they were stained) but were
detected because counts were obtained by the gamma
probe, for the lymph nodes that were only stained, for
the lymph nodes that were detected with radioactivity
only (hot), and for the lymph nodes that both retained
the dye and were detected as radioactive (stained-hot).
In patients who underwent ALND, the total numbers of
lymph nodes removed and their metastatic states were
determined separately.
Results
A total of 42 patients were included in our study. All of
the patients were female and their average age was 51.3 ±
11.9 years. The demographic and clinical characteristics of
the patients are shown in Table 1. In one patient who
underwent direct ALND, no SLN was detected by
lymphoscintigraphy, gamma probe, or blue dye, and no
metastasis was observed in the axilla of this patient. In the
remaining 41 patients, at least one stained-only, hot-only,
or stained-hot SLN was found.
In our study, at least one blue-stained SLN was found
in the first surgical stage (the stage in which only the
blue-stained lymph nodes were detected). In the first
stage, a total of 87 stained nodes were extracted.
Seventy-one of these nodes were also found to be hot by
ex-vivo counting. In the second stage, in which remnant
hot lymph nodes in the axilla were detected with gammahand probe guidance, a total of 34 hot nodules were re-
moved. Three of these were stained nodes that we could
not detect in the first stage in three different patients.
These findings did not affect the decision to perform ax-
illary dissection because of same metastatic status of
these nodes. A total of 74 stained-hot nodes were
extracted from 41 patients. Nineteen patients had 23
metastatic lymph nodes. The ratio of metastatic nodes
was 31.08% in the stained-hot node group.





Number of lymph nodes removed 87 121
Average number of lymph nodes
removed (SD)
2.1 3.0
Number of stained-hot lymph nodes
missed at the blue dye stage (%)
3 (3.2)
Number of patients with different
frozen-section results with the blue
dye and combination methods (%)
0 (0)
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eight patients. Four of these eight had a total number of
five metastatic lymph nodes. The metastatic status of
these nodes was correlated with the metastatic status of
the stained-hot lymph nodes in each single patient. The
ratio of metastatic nodes was 31.3% in the stained-only
group.
In the second stage, 34 hot nodes were removed from
19 patients (3 of these nodes were missed stained-hot
nodes that were not found in the first stage). Three
metastatic lymph nodes were found in three different
patients in this group. The metastatic status of these
nodes was correlated with the stained-hot nodes in each
single patient. The ratio of metastatic nodes was 8.83%
in the hot-only group.
The total number of stained lymph nodes was 90, and
the ratio of metastatic nodes was 31.1%. The total num-
ber of hot nodes was 108, and the ratio of metastatic
nodes was 24.1%.
In the first stage, the average number of SLNs re-
moved was 2.1 ± 1.1. In the second stage of surgery (the
stage in which the nodes that gave axillary counts were
detected), at least one additional hot node was removed
from 41 patients, or at least one of the nodes that was
removed in the first stage because it was blue was also
hot. With the gamma probe, 34 hot lymph nodes were
excised from 21 patients in addition to the lymph nodes
that were already removed in the dye stage (median, 1;
average, 1.6; range, 1–4). Overall, the average number of
hot lymph nodes that were removed was 2.9 ± 1.5. In
three patients (7% of all patients) with additional lymph
node removals, these single hot lymph nodes were also
stained, but were not noted during the first stage of the
procedure. In all patients, including these three patients,
FS and subsequent histopathological examinations of the
SLNs that were removed later and the SLNs that were re-
moved first were 100% concordant and did not affect the
decision to perform axillary curettage (Tables 2 and 3).





n % n %
Number of patients recruited to the study 42 100 42 100
Number of patients with SLN detected 41 97.6 41 97.6
Number of patients with positive SLN 19 45.2 19 45.2
Number of patients with negative SLN 22 53.7 22 53.7
Number of patients with stained-hot lymph
nodes that were missed during the blue
dye stage (%)
3 (7.1)
Number of patients with different frozen
section results with the blue dye and
combination methods
0 (0)of whom had positive axillary lymph nodes (46%). As a
result of ALND, an average of 19.7 ± 5.6 (range, 10–29)
lymph nodes were dissected.
Discussion
The SLN can be defined as the first lymph node that re-
ceives the lymphatic drainage of the region containing
the primary tumour. SLNB is now a standard technique
that is applied to early-stage breast cancer with clinically
negative axillae; it can predict the presence of metastasis
with a high rate of accuracy [4,15]. Technically, SLNB
can be applied using only dye, only radioactivity, or a
combination of these two methods. All three methods
can reportedly be applied with high rates of detection,
sensitivity, and accuracy and with acceptable false-
negative rates [10].
Performance of SLNB with blue dye only is a more in-
expensive and easier technique to apply compared with
the combination method because it does not require in-
volvement of the nuclear medicine department. In stud-
ies using these methods, the success rates of finding
SLNs are reported to be 41% to 100% with the dye-only
method, 69% to 100% with the radioisotope-only
method, and 76% to 100% with the combination method
[16-18]. Kim et al. investigated 69 clinical studies
performed between 1970 and 2003 and calculated a
false-negative rate of 10.9% with the dye-only method,
8.8% with the radiocolloid-only method, and 7% with the
combination method in their meta-analysis [16]. The
relatively low success rates reported in the literature for
SLNBs performed with the dye-only method can be
explained by the fact that in these studies, the initial
SLNB was performed with the dye-only method [7].
When comparing the dye-only and combination
methods, Radovanovic et al. reported that in their pro-
spective randomised study with 150 patients, although
there was no significant difference in the number of lymph
nodes removed, the combination technique was superior
in its negative predictive value and overall accuracy rates.
In this study, the negative predictive value was 86.9% in
the dye-only group and 95.3% in the combination group;
the overall accuracy was 68% in the dye-only group and
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prospective randomised study with 329 patients, reported
similar results for the two methods and stressed that
in institutions without nuclear medicine capability,
SLNB can be performed using the dye-only method.
and Meyer-Rochow et al. reported comparable findings
in their randomised study with 104 patients [14,19].
Koukouraki et al. found that the SLN detection rate was
higher with the combination method in their randomised
study with 501 patients, but Kern et al. reported a high
concordance between the two methods in their study with
185 patients, and similar numbers of SLN detection ratios
were obtained with both techniques [12,20].
Three reviews have been published regarding SLNs: in
2006, Steven et al. reported that all of the methods could
be performed with similar SLN detection and false-
negative rates when they were performed by experienced
surgeons; in 2007, Sato et al. reported that the dye and
combination methods returned the same results and that
the radioisotope added extra cost and potential radio-
activity damage risk; and in 2008, Collins reported that
radiopharmaceutical-only SLNB was superior to dye-
only SLNB but that only the combination method had
the potential to maximise the correct staging [5,6,9].
In all of the above-mentioned studies, SLNB was
performed by two surgical teams and, as required by the
randomisation, the dye-only group and the combination
group comprised different patients. Because of this, the
surgeon and patient factors could not be equalised in
these studies. Our study design is novel because these
two factors were completely equalised by having the
same surgeon perform all of the surgeries and by apply-
ing both techniques to the same patient group.
In our study, as a result of adding the radioisotope to
the blue dye, 34 additional lymph nodes were excised
from 42 patients; this number is quite high compared
with other studies in the literature. In addition, the aver-
age number of lymph nodes that were identified for re-
moval by the combination method was significantly
higher than the number of lymph nodes removed by the
dye-only method. Despite this high additional lymph
node dissection, the lymph nodes first removed from the
axilla using the dye-only method, the hot-only nodes
that were removed later, and the stained-hot nodes that
were not missed during the first stage were 100% con-
cordant in terms of metastasis and did not change the
decision to perform axillary curettage.
The mean age was low in our present study because of
the limited number of patients. In general, the mean age
of the patients who undergo breast cancer surgeries in
our institution is higher. Furthermore, in Turkey, the
mean age of patients with breast cancer is correlated
with world numbers. We believe that the low mean age
in our present study was incidental.SLNB may be difficult in obese patients. In the present
study, we did not evaluate body mass indices, which is a
limitation.
Although the addition of the radioisotope tracer
method increases the number of lymph nodes excised
from the axilla, it was not found to be superior to the
dye-only method with respect to the SLNB detection
rates and determination of axilla positivity; furthermore,
it did not change the ALND decision for any of the pa-
tients. In this context, when the side effects of the com-
bination method (which are perhaps due to the
potentially unnecessary removal of additional lymph
nodes) are taken into account, we conclude that SLNB
should be performed with the dye-only method. The
present study is an original surgical method performed
by the same surgeon without the need for a control
group. Some authors believe that this method does not
bring any additional data to the literature and may result
in excessive lymph node dissection.Conclusions
We believe that the dye-only method is sufficient for
SLNB dissection. Results based on a small selected sam-
ple, as in the present study, will not lend to powerful
conclusions. We believe that the number of patients in
future studies must be increased.Consent
All of the patients included in the study were informed
about the study in detail, and informed consent forms
were obtained. The copies of the written consents are
available for review by the Editor-in-Chief of this
journal.
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